Novartis Message Board - Msg: 13263987

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 122.63

+0.7%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jack Hartmann who wrote (271)	3/23/2000 8:19:00 AM
From: Jack Hartmann	Read Replies (1) of 296

Novartis Unit: FDA OKs Lamisil For Over-The-Counter Mkt Dow Jones Newswires 3/22/2000 SUMMITT, N.J. -- Novartis AG's (Z.NOV) Novartis Consumer Health unit said the Food and Drug Administration approved switching the company's Lamisil Solution drug to over-the-counter from prescription status. In a press release Tuesday, the pharmaceutical company said it will introduce new liquid Lamisil products for treating athlete's foot, jock itch and ringworm in the spring. The FDA decision follows a similar March 1999 ruling allowing the company's Lamisil cream to be sold over the counter. The company's Lamisil tablets will remain available only by prescription. -Michael Goodman; Dow Jones Newswires Wonder if we'll see advertising on TV. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next